Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
E1A11
Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma
- NCT01863550 ↗
- Active, not recruiting
- ECOG-ACRIN Cancer Research Group
- Deep
We haven't built an HCP commentary report on E1A11 (bortezomib, carfilzomib and 2 more in Plasma Cell Myeloma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on E1A11 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 132 | |
| YouTube | 17 | |
| Podcasts | 2 | |
| Bluesky threads | 2 |
The trial
ClinicalTrials.gov- Official title
- Randomized Phase III Trial of Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide, and Dexamethasone (CRd) Followed by Limited or Indefinite Duration Lenalidomide Maintenance in Patients With Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Plasma Cell Myeloma
- Interventions
- Bortezomib; Carfilzomib; Dexamethasone; Laboratory Biomarker Analysis; Lenalidomide; Quality-of-Life Assessment
- Arms
- Arm A (bortezomib, lenalidomide, dexamethasone) · Experimental
- Arm B (carfilzomib, lenalidomide, dexamethasone) · Experimental
- Arm C (lenalidomide) · Experimental
- Arm D (lenalidomide) · Experimental
- Enrollment
- 1,087
- Primary outcomes
- Overall survival (OS) for the maintenance analysis
- Progression-free survival for the induction analysis
- Sponsor
- ECOG-ACRIN Cancer Research Group with National Cancer Institute (NCI)
- Start
- Dec 6, 2013
- Primary completion
- Dec 31, 2026 (estimated)
- Results posted
- No
- Registry record
- NCT01863550 · updated Oct 5, 2026
Publications
linked from the registry- Kumar S, Jacobus S, Cohen A, Weiss M, Callander N, Singh A, Parker T, Green M, Thertulien R, Parsons B, Kumar P, Kapoor P, Rosenberg A, Dib E, Almquist D, Zonder J, Faber E, Wei Z, Anderson K, Lonial S, Richardson P, Orlowski R, Wagner L, Rajkumar SV. Continuous or Fixed-Duration Maintenance Therapy in Multiple Myeloma. N Engl J Med. 2026 Jul 16;395(3):221-232. doi: 10.1056/NEJMoa2600157. PubMed 42456135
- Kumar SK, Jacobus SJ, Cohen AD, Weiss M, Callander N, Singh AK, Parker TL, Menter A, Yang X, Parsons B, Kumar P, Kapoor P, Rosenberg A, Zonder JA, Faber E Jr, Lonial S, Anderson KC, Richardson PG, Orlowski RZ, Wagner LI, Rajkumar SV. Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol. 2020 Oct;21(10):1317-1330. doi: 10.1016/S1470-2045(20)30452-6. Epub 2020 Aug 28. PubMed 32866432